Suppr超能文献

长效钙拮抗剂逆转OLETF糖尿病大鼠心脏中升高的转化生长因子β1和内皮素-1的表达

Reversal of elevated cardiac expression of TGFbeta1 and endothelin-1 in OLETF diabetic rats by long-acting calcium antagonist.

作者信息

Jesmin Subrina, Zaedi Sohel, Maeda Seiji, Mowa Chishimba N, Sakuma Ichiro, Miyauchi Takashi

机构信息

Department of Cardiovascular Medicine, Institute of Clinical Medicine, University of Tsukuba, Ibaraki 305-8575, Japan.

出版信息

Exp Biol Med (Maywood). 2006 Jun;231(6):907-12.

Abstract

The effects of calcium channel blockers (CCBs) on complications associated with diabetes mellitus (DM) have been well studied in clinical and basic science investigations. Cardiovascular complications are a common feature of type 2 DM, and insulin resistance is an early clinical manifestation of type 2 DM. CCBs are widely used to treat cardiovascular diseases in patients with DM. In this study, we used a spontaneous type 2 diabetic rat model, Otsuka Long-Evans Tokushima Fatty (OLETF) rats, at a highly insulin-resistant stage with modest hyperglycemia. We examined cardiac expression of transforming growth factor-beta(1) (TGFbeta(1)) and endothelin-1 (ET-1) in male OLETF rats. At 8 weeks of age, OLETF rats were treated for 12 weeks with the long-acting CCB benidipine (1 mg/kg/day or 3 mg/kg/day, po, n = 12), with hydralazine hydrochloride (3 mg/kg/day, po, n = 12), or with vehicle (OLETF, n = 12), and male age-matched genetic control Long-Evans Tokushima Otsuka (LETO, n = 12) rats were used. Blood pressure was significantly higher in OLETF rats than in LETO rats, and benidipine treatment at both dosages in OLETF rats for 12 weeks did not significantly reduce blood pressure, whereas hydralazine treatment significantly lowered blood pressure in OLETF rats. Hydralazine and both dosages of benidipine significantly reduced upregulated cardiac ET-1 levels in OLETF rats. Plasma and cardiac TGFbeta1 levels were remarkably higher in OLETF rats compared with LETO rats and were normalized by treatment with benidipine (3 mg/kg/day). Our results suggest that CCBs are effective in normalizing upregulated cardiac TGFbeta1 and ET-1 levels at the insulin-resistant stage in OLETF rats, which may improve cardiac morphology and function in this rat model without altering blood pressure and plasma glucose levels. In contrast, hydralazine treatment also normalizes cardiac ET-1 levels while significantly reducing blood pressure.

摘要

钙通道阻滞剂(CCB)对糖尿病(DM)相关并发症的影响已在临床和基础科学研究中得到充分研究。心血管并发症是2型糖尿病的常见特征,而胰岛素抵抗是2型糖尿病的早期临床表现。CCB被广泛用于治疗糖尿病患者的心血管疾病。在本研究中,我们使用了自发性2型糖尿病大鼠模型,即大冢长-艾氏-德岛肥胖(OLETF)大鼠,处于高度胰岛素抵抗阶段且伴有轻度高血糖。我们检测了雄性OLETF大鼠心脏中转化生长因子-β1(TGFβ1)和内皮素-1(ET-1)的表达。8周龄时,OLETF大鼠接受长效CCB贝尼地平(1毫克/千克/天或3毫克/千克/天,口服,n = 12)、盐酸肼屈嗪(3毫克/千克/天,口服,n = 12)或载体(OLETF,n = 12)治疗12周,并使用年龄匹配的雄性基因对照大冢-德岛长-艾氏(LETO,n = 12)大鼠。OLETF大鼠的血压显著高于LETO大鼠,OLETF大鼠接受两种剂量的贝尼地平治疗12周均未显著降低血压,而肼屈嗪治疗显著降低了OLETF大鼠的血压。肼屈嗪和两种剂量的贝尼地平均显著降低了OLETF大鼠心脏中上调的ET-1水平。与LETO大鼠相比,OLETF大鼠的血浆和心脏TGFβ1水平显著更高,而用贝尼地平(3毫克/千克/天)治疗可使其恢复正常。我们的结果表明,CCB可有效使OLETF大鼠胰岛素抵抗阶段心脏中上调的TGFβ1和ET-1水平恢复正常,这可能改善该大鼠模型的心脏形态和功能,而不改变血压和血糖水平。相比之下,肼屈嗪治疗也可使心脏ET-1水平恢复正常,同时显著降低血压。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验